Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Combination Product: Connected Solution with H2S app which connects with blood glucose meter (BGM)

First Posted Date: 2023-01-13

Last Posted Date: 2024-07-17

Lead Sponsor: Sanofi

Target Recruit Count: 200

Registration Number: NCT05684341

Locations: 🇨🇳
Tri-Service General Hospital - Investigational Site Number: 1580014, Taipei city, Taiwan
🇨🇳
Kaohsiung Veterans General Hospital - Investigational site number 1580010, Kaohsiung, Taiwan
🇨🇳
Far-Eastern Memorial Hospital - Investigational Site Number: 1580004, New Taipei city, Taiwan

and more 11 locations

Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab

First Posted Date: 2023-01-11

Last Posted Date: 2025-02-10

Lead Sponsor: Sanofi

Target Recruit Count: 34

Registration Number: NCT05680298

Locations: 🇨🇳
Beijing Children's hospital, Beijing, China

Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)

Completed

Conditions: Fabry Disease

First Posted Date: 2023-01-05

Last Posted Date: 2024-03-06

Lead Sponsor: Sanofi

Target Recruit Count: 15

Registration Number: NCT05671770

Locations: 🇦🇪
Cleveland Clinic AbuDhabi, Abu Dhabi, United Arab Emirates

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Isatuximab intravenous (IV)
Drug: Cemiplimab (SAR439684)
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Isatuximab subcutaneous (SC)
Drug: Carfilzomib

First Posted Date: 2023-01-03

Last Posted Date: 2025-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 70

Registration Number: NCT05669989

Locations: 🇺🇸
Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺
Investigational Site Number : 0360006, Blacktown, New South Wales, Australia
🇦🇺
Investigational Site Number : 0360001, Saint Leonards, New South Wales, Australia

and more 34 locations

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Phase 3

Active, not recruiting

Conditions: Hemophilia

Interventions: Drug: Fitusiran
Drug: Clotting factor concentrates (CFC) or bypassing agents (BPA)
Drug: Antithrombin concentrate (ATIIIC)

First Posted Date: 2022-12-22

Last Posted Date: 2024-10-22

Lead Sponsor: Sanofi

Target Recruit Count: 79

Registration Number: NCT05662319

Locations: 🇺🇸
Center for Inherited Blood Disorders (CIBD) Site Number : 8400012, Orange, California, United States
🇺🇸
University of California San Diego Site Number : 8400011, San Diego, California, United States
🇺🇸
University of Minnesota Site Number : 8400016, Minneapolis, Minnesota, United States

and more 55 locations

A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region

Completed

Conditions: Chronic Rhinosinusitis With Nasal Polyps

First Posted Date: 2022-12-14

Last Posted Date: 2024-07-11

Lead Sponsor: Sanofi

Target Recruit Count: 148

Registration Number: NCT05649813

Locations: 🇰🇼
Investigational Site Number: 01, Kuwait, Kuwait

A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

Phase 2

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: SAR443820
Other: Placebo

First Posted Date: 2022-11-29

Last Posted Date: 2024-12-13

Lead Sponsor: Sanofi

Target Recruit Count: 174

Registration Number: NCT05630547

Locations: 🇧🇪
Investigational Site Number : 0560001, Bruxelles, Belgium
🇧🇬
Investigational Site Number : 1000002, Sofia, Bulgaria
🇨🇦
Investigational Site Number : 1240002, Ottawa, Ontario, Canada

and more 32 locations